Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1) | Zendy

R. Loch Macdonald | Zendy; Neal F. Kassell | Zendy; Stephan A. Mayer | Zendy; Daniel Ruefenacht | Zendy; Peter Schmiedek | Zendy; Stephan Weidauer | Zendy; Aline Frey | Zendy; Sébastiên Roux | Zendy; A. Pasqualin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1)

Author(s) -

R. Loch Macdonald,

Neal F. Kassell,

Stephan A. Mayer,

Daniel Ruefenacht,

Peter Schmiedek,

Stephan Weidauer,

Aline Frey,

Sébastiên Roux,

A. Pasqualin

Publication year - 2008

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.108.519942

Subject(s) - medicine , subarachnoid hemorrhage , ischemia , stroke (engine) , infarction , brain ischemia , cardiology , anesthesia , myocardial infarction , mechanical engineering , engineering

This randomized, double-blind, placebo-controlled, dose-finding study assessed efficacy and safety of 1, 5, and 15 mg/h intravenous clazosentan, an endothelin receptor antagonist, in preventing vasospasm after aneurysmal subarachnoid hemorrhage.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research